ArticleInfection and immunity1989
Efficacy of interleukin-1 beta against systemic Candida albicans infections in normal and immunosuppressed mice.
Article in Infection and immunity, 1989. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 37 citations in OpenAlex.
- Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice.Infection and immunity · 2000Article
- Macrophages in resistance to candidiasis.Microbiology and molecular biology reviews : MMBR · 1997Review
- A protective role of platelet-activating factor in murine candidiasis.Infection and immunity · 1997Article
- Production and function of cytokines in natural and acquired immunity to Candida albicans infection.Microbiological reviews · 1995Review
- Tumor necrosis factor and interleukin-6 in Candida albicans infection in normal and granulocytopenic mice.Infection and immunity · 1992Article
- Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in neutropenic mice.Antimicrobial agents and chemotherapy · 1992Article
- Role of granulocytes in increased host resistance to Candida albicans induced by recombinant interleukin-1.Infection and immunity · 1990Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prophylactic treatments with either recombinant human interleukin-1 beta (rHuIL-1 beta) or a muramyl dipeptide analog ([Abu1]MDP) enhanced the resistance of mice to systemic infection with Candida albicans. The optimum treatment regimen in both normal and cyclophosphamide-treated mice was intraperitoneal administration of 100 ng of rHuIL-1 beta or 1.6 mg of [Abu1]MDP per mouse once daily for 3 consecutive days before infection. Neither rHuIL-1 beta nor [Abu1]MDP was efficacious when started after the infection or when given before cyclophosphamide to mice infected subsequently. Continuing to treat after the infection with either drug neither enhanced nor antagonized the efficacy of prophylactic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.